Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
A novel gene (designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P1E1B can be used in active or passive immunization.
1. A method of generating a mammalian immune response, comprising:
exposing cells of the mammal's immune system to an immunogenic portion of
a) a protein comprising the amino acid sequence of SEQ ID NO:2983 or SEQ ID NO:2985; or
b) a nucleotide sequence that encodes said protein;
whereby an immune response is generated to the protein.
2. The method of claim 1 , wherein the protein comprising the amino acid sequence of SEQ ID NO:2983 or SEQ ID NO:2985, wherein the protein comprises at least one T cell or at least one B cell epitope.
3. The method of claim 2 , wherein the immune response comprises an induced B cell that generates antibodies that specifically bind the protein comprising the amino acid sequence of SEQ ID NO:2983 or SEQ ID NO:2985.
4. The method of claim 2 wherein the immune response comprises activation of a cytotoxic T cell (CTL), whereby the activated CTL kills an autologous cell that expresses the protein comprising the amino acid sequence of SEQ ID NO:2983 or SEQ ID NO:2985.
5. The method of claim 4 wherein the immune response comprises a helper T cell (HTL), whereby the activated HTL secretes cytokines that facilitate the cytotoxic activity of a cytotoxic T cell (CTL) or the antibody producing activity of a B cell.